{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:56:05Z","timestamp":1790070965403,"version":"4.0.1"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"1314","license":[{"start":{"date-parts":[[2012,3,25]],"date-time":"2012-03-25T00:00:00Z","timestamp":1332633600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>PRINCIPLES:  The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines  aim to optimise chronic obstructive pulmonary disease (COPD) diagnosis and  treatment.\n        However,  little is known about the extent to which general practitioners\u2019 (GP) adherence  to GOLD guidelines improves patient outcomes.\n        METHODS:  In this questionnaire-based study, COPD patients were screened and enrolled;  exacerbation history was recorded, and demographic, spirometric and management  data were collected for 12 months. Spirometry was performed at least every 6  months according to American Thoracic Society guidelines. Based on these data,  patients were grouped into GOLD COPD severity classifications. Data were  expressed as the difference between baseline and month 12.\n        RESULTS: Among  139 GPs, 454 patients were analysed regarding baseline and 12 month data. There  was no significant change in distribution of GOLD COPD severity grades, lung  function or guideline adherence. Chronic cough and sputum production were  significantly reduced (p &lt;0.001; p &lt;0.020), as was exacerbation rate (p = 0.041). Factors associated with exacerbations  were male sex, asthma and cerebrovascular insult as a co-morbidity.  Exacerbation rate was significantly reduced in patients treated with  combination therapy (long-acting \u03b22-agonist (LABA)+ inhaled corticosteroids (ICS); p = 0.0178) and long-acting  anticholinergics (LAAC; p = 0.0011).  Patients treated per guidelines had no advantage in lung function, estimation  of symptom prevalence or, most importantly, exacerbation rate.\n        CONCLUSIONS:  While there was no improvement in adherence to GOLD guidelines, disease  severity was not affected detrimentally, suggesting that guideline adherence  does not seem to impact symptom prevalence, exacerbation rate or lung function  decline after one year of follow up.<\/jats:p>","DOI":"10.4414\/smw.2012.13567","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T05:57:14Z","timestamp":1334210234000},"page":"w13567","source":"Crossref","is-referenced-by-count":17,"title":["Impact of adherence to GOLD guidelines on symptom prevalence, lung  function decline and exacerbation rate in\u00a0a\u00a0Swiss COPD cohort"],"prefix":"10.57187","volume":"142","author":[{"given":"Anja","family":"Jochmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Christian","family":"Jochmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miedinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Schafroth T\u00f6r\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant N.","family":"Chhajed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg Daniel","family":"Leuppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36756","published-online":{"date-parts":[[2012,3,25]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1457\/1798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1457\/1799","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1457\/1798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T03:40:44Z","timestamp":1755229244000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/1457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,25]]},"references-count":0,"journal-issue":{"issue":"1314","published-online":{"date-parts":[[2012,3,26]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2012.13567","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,25]]}}}